Entero Therapeutics, Inc.
ENTO
$0.47
-$0.0143-2.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 805.60K | 1.28M | 1.69M | 3.21M | 8.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 821.40K | 1.20M | 1.89M | 3.43M | 9.10M |
| Operating Income | -821.40K | -1.20M | -1.89M | -3.43M | -9.10M |
| Income Before Tax | -948.10K | -1.19M | -1.90M | -3.43M | -9.10M |
| Income Tax Expenses | -- | -- | -- | 4.26M | -14.86M |
| Earnings from Continuing Operations | -948.10K | -11.80M | -1.90M | -7.69M | 5.76M |
| Earnings from Discontinued Operations | -311.50K | -439.50K | -685.70K | -1.12M | -192.80K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.26M | -12.24M | -2.58M | -8.81M | 5.57M |
| EBIT | -821.40K | -1.20M | -1.89M | -3.43M | -9.10M |
| EBITDA | -817.70K | -1.24M | -1.89M | -3.39M | -9.09M |
| EPS Basic | -0.28 | -3.23 | -0.59 | -3.86 | 3.12 |
| Normalized Basic EPS | -0.12 | 0.30 | -0.26 | -0.93 | -3.23 |
| EPS Diluted | -0.33 | -3.23 | -0.59 | -3.86 | 0.37 |
| Normalized Diluted EPS | -0.12 | 0.30 | -0.26 | -0.93 | -0.39 |
| Average Basic Shares Outstanding | 4.77M | 3.43M | 4.55M | 2.29M | 1.76M |
| Average Diluted Shares Outstanding | 4.77M | 3.43M | 4.55M | 2.29M | 14.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |